Mike Kratky
Stock Analyst at Leerink Partners
(3.50)
# 918
Out of 4,914 analysts
29
Total ratings
52.38%
Success rate
30.96%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Initiates: Outperform | $118 | $106.47 | +10.83% | 1 | Jun 16, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $92.44 | +19.00% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $14.66 | +91.00% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $14.00 | -14.29% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $89.35 | -2.63% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $129.59 | +52.02% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $227.15 | +15.78% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $16.69 | +169.62% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $8.80 | +150.00% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $291.49 | -36.88% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $39.86 | +5.37% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $496.87 | -31.17% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $80.47 | -6.80% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $53.84 | -31.28% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $13.43 | -32.99% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $3.59 | +1,292.76% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.46 | +2,982.19% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $295.48 | +6.61% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $43.72 | -29.09% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $16.66 | -15.97% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $16.80 | +138.17% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $11.34 | +3,286.24% | 1 | Aug 11, 2022 |
Boston Scientific
Jun 16, 2025
Initiates: Outperform
Price Target: $118
Current: $106.47
Upside: +10.83%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $92.44
Upside: +19.00%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $14.66
Upside: +91.00%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $14.00
Upside: -14.29%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $89.35
Upside: -2.63%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $129.59
Upside: +52.02%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $227.15
Upside: +15.78%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $16.69
Upside: +169.62%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $8.80
Upside: +150.00%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $291.49
Upside: -36.88%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $39.86
Upside: +5.37%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $496.87
Upside: -31.17%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $80.47
Upside: -6.80%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $53.84
Upside: -31.28%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $13.43
Upside: -32.99%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $3.59
Upside: +1,292.76%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.46
Upside: +2,982.19%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $295.48
Upside: +6.61%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $43.72
Upside: -29.09%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $16.66
Upside: -15.97%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $16.80
Upside: +138.17%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $11.34
Upside: +3,286.24%